Free Trial
LON:AGY

Allergy Therapeutics (AGY) Share Price, News & Analysis

Allergy Therapeutics logo
GBX 7.70 0.00 (0.00%)
As of 11:46 AM Eastern

About Allergy Therapeutics Stock (LON:AGY)

Key Stats

Today's Range
7.05
8
50-Day Range
5
7.70
52-Week Range
1.80
8
Volume
230,809 shs
Average Volume
682,001 shs
Market Capitalization
£367.29 million
P/E Ratio
N/A
Dividend Yield
8.33%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group has achieved over 9% compound annual growth since formation and employs c.500 employees.

Receive AGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGY Stock News Headlines

I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Allergy Therapeutics Seeks Approval for Grass Allergy Treatment
Allergy Therapeutics Unveils Incentive Plans and Share Repurchase
Allergy Therapeutics Shows Financial Turnaround and Clinical Progress
Allergy Therapeutics Sees Growth and Strategic Advances
See More Headlines

AGY Stock Analysis - Frequently Asked Questions

Allergy Therapeutics' stock was trading at GBX 6.53 on January 1st, 2025. Since then, AGY stock has increased by 18.0% and is now trading at GBX 7.70.
View the best growth stocks for 2025 here
.

Allergy Therapeutics plc (LON:AGY) posted its quarterly earnings data on Wednesday, November, 6th. The company reported ($1.07) earnings per share (EPS) for the quarter. Allergy Therapeutics had a negative trailing twelve-month return on equity of 155.90% and a negative net margin of 94.29%.

Shares of AGY stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Allergy Therapeutics investors own include (RLYP) (RLYP), Royalty Pharma (RPRX), genedrive (GDR), Intel (INTC), IQE (IQE), AstraZeneca (AZN) and Babcock International Group (BAB).

Company Calendar

Last Earnings
3/04/2020
Today
1/21/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
612
Year Founded
N/A

Profitability

Net Income
£-50,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£53.26 million
Cash Flow
GBX 2.11 per share
Book Value
GBX 1 per share

Miscellaneous

Outstanding Shares
4,770,000,000
Free Float
N/A
Market Cap
£367.29 million
Optionable
Not Optionable
Beta
1.40
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (LON:AGY) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners